Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Pembrolizumab trumps chemotherapy in recurrent head and neck cancer

pharmaceutical-technologyJune 05, 2019

Tag: pembrolizumab , chemotherapy , cancer

PharmaSources Customer Service